Anebulo Pharmaceuticals (ANEB) said Wednesday that its board of directors and a special committee of independent directors have recommended a reverse stock split at a ratio of not less than 1-for-2,500 and not greater than 1-for-7,500, as part of its going private transactions.
The company said the reverse stock split is intended to reduce Anebulo's stockholders enough to allow the company to terminate its registration as a US Securities and Exchange Commission reporting company.
Under the reverse stock split, the company's stockholders will receive cash in the amount of $3.50 per pre-split share in exchange for any fractional shares of post-split stock.
Shares of the company were up 73% in recent Wednesday tracing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.